Arrowhead Pharmaceuticals (MEX:ARWR) Interest Expense: MXN-1,692 Mil (TTM As of Mar. 2026)


MEX:ARWR Arrowhead Pharmaceuticals Inc MEX:ARWR
49 GF Score
Price MXN454.55
GF Value MXN279.99
! 7 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Interest Expense?

Arrowhead Pharmaceuticals MEX:ARWR 49 Interest Expense is MXN-1,692 Mil as of Mar. 2026. GuruFocus rates MEX:ARWR with a GF Score™ of 49/100 and a GF Value™ of MXN279.99. The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Arrowhead Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was MXN -430 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-1,692 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Arrowhead Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was MXN -2,547 Mil. Arrowhead Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was MXN -430 Mil. Arrowhead Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Arrowhead Pharmaceuticals  (MEX:ARWR) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Arrowhead Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was MXN-430 Mil. Its Operating Income for the three months ended in Mar. 2026 was MXN-2,547 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was MXN16,981 Mil.

Arrowhead Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Arrowhead Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Arrowhead Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Interest Expense Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -319.22 -637.02 -1,639.26

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -442.70 -459.09 -397.96 -405.22 -430.01
MEX:ARWR
49GF Score
Arrowhead Pharmaceuticals Inc MEX:ARWR
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,692 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of MXN-1,692 Mil mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a Interest Expense of MXN-1,692 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Interest Expense too high?
Arrowhead Pharmaceuticals' current Interest Expense is MXN-1,692 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Interest Expense compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Interest Expense of MXN-1,692 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Interest Expense is MXN-1,692 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Interest Expense of MXN-1,692 Mil. The stock's GF Value™ is MXN279.99, compared to a current price of MXN454.55 — trading 62.3% above its estimated fair value. The current Interest Expense is MXN-1,692 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Interest Expense is MXN-1,692 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of MXN454.55 is trading 62.3% above its estimated GF Value™ of MXN279.99.

Key valuation signals for MEX:ARWR:

  • Interest Expense: MXN-1,692 Mil
  • GF Value™: MXN279.99 vs. price of MXN454.55 (62.3% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for MEX:ARWR

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.55
Price
MXN279.99
GF Value